ARTICLE | Clinical News
Y-90 epratuzumab regulatory update
November 17, 2008 8:00 AM UTC
FDA granted Orphan Drug designation to Immunomedics for epratuzumab to treat acute lymphoblastic leukemia (ALL). The humanized mAb against CD22 is in Phase II testing to treat B cell ALL. ...